Eight companies with immunotherapy approaches for brain tumors
2012 Preview: Cancer Immunotherapy Catalysts
December 14, 2011 By 1 Comment
2012 represents a period with robust news flow for emerging immuno-oncology companies
Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution
September 18, 2011 By Leave a Comment
Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.
Cancer Immunotherapy: A Roundtable Discussion
June 30, 2011 By 3 Comments
Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.
Ipilimumab Approval Highlights Immunotherapy Renaissance
March 25, 2011 By Leave a Comment
On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.
Follow MD Becker Partners